RedHill Biopharma(NASDAQ) RDHL

Market Cap$3.95M

Since IPO (2013)-100%

5 Year-100%

1 Year-50%

1 Month-22%

$0.64

-5.84%

-0.04Today

RedHill Biopharma last closing stock price
Metric	Price	Date
Last close	USD 0.65	2026-07-31

RedHill Biopharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+2.64%	USD 0.63	2026-07-24
1 month	-21.68%	USD 0.83	2026-07-01
3 month	-40.09%	USD 1.09	2026-05-01
Year to date	-36.89%	USD 1.03	2025-12-31
1 year	-50.38%	USD 1.31	2025-07-31
3 year	-97.92%	USD 31.25	2023-08-01
5 year	-99.99%	USD 6,440.00	2021-07-30
Since inception	-99.99%	USD 11,100.00	2013-01-07

RedHill Biopharma Financials at a Glance

Market Cap

$3.95M

Revenue (TTM)

$9.55M

Net Income (TTM)

-$9.31M

EPS (TTM)

$0.00

P/E Ratio

-0.01

Dividend

$0.00

Beta (Volatility)

1.23 (Average)

Dividend

$0.00

Beta (Volatility)

1.23 (Average)

Price

$0.64

Volume

20,556.2

Open

$0.65

Price

$0.64

Volume

20,556.2

Open

$0.65

Previous Close

$0.65

Daily Range

$0.65 - $0.66

52-Week Range

$0.63 - $2.79

Estimated Earnings Date

Aug 20, 2026

Dividend

$0.00

Beta (Volatility)

1.23 (Average)

Price

$0.64

Volume

20,556.2

Open

$0.65

Previous Close

$0.65

Daily Range

$0.65 - $0.66

52-Week Range

$0.63 - $2.79

Estimated Earnings Date

Aug 20, 2026

RDHL News

A medical professional using a microscope

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About RedHill Biopharma

RedHill Biopharma Ltd. is a specialized pharmaceutical company focused on developing and commercializing innovative therapies for gastrointestinal diseases and infections. The company offers a range of medications and has a robust pipeline of investigational compounds aimed at addressing unmet medical needs.

Products and Services

Movantik for opioid-induced constipation in adults
Talicia for treating Helicobacter pylori infections
Aemcolo for travelers' diarrhea in adults

Growth Outlook

RHB-204 is in Phase 3 trials for pulmonary nontuberculous mycobacteria infections
Opaganib has completed Phase 2 for severe COVID-19 pneumonia
RHB-104 is advancing in Phase 3 for Crohn's disease treatment

Financial Highlights

Q2 2025 revenue of $2.04 million, consistent with Q1 2025
Gross profit margin of 60.6% indicates strong product demand
Cash and short-term investments totaled $3.97 million as of Q2 2025

RedHill Biopharma Ltd. has established itself as a key player in the pharmaceutical industry, particularly in the gastrointestinal sector. The company's product offerings, including Movantik, Talicia, and Aemcolo, address significant health issues, providing effective solutions for patients. The ongoing clinical trials for investigational compounds like RHB-204 and Opaganib highlight the company's commitment to innovation and expanding its therapeutic portfolio. The growth outlook remains promising, with several compounds in advanced stages of development. The successful progression of RHB-204 and Opaganib could lead to new treatment options for patients and potential revenue streams for the company. Financially, RedHill Biopharma has shown resilience, with a stable revenue stream and a solid gross profit margin. The cash position of $3.97 million as of Q2 2025 provides a buffer for ongoing operations and research activities. Overall, RedHill Biopharma Ltd. presents an intriguing opportunity for investors interested in the healthcare sector, particularly in companies focused on innovative therapies for unmet medical needs.

AI Generated • Jul 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Dror Ben-Asher

Website

www.redhillbio.com

Headquarters

Tel Aviv, TA 6473921, IL

RDHL Financials

Key Financial Metrics (TTM)

Gross Margin

60.60%

Operating Margin

-107.33%

Net Income Margin

-101.32%

Return on Equity

5740.28%

Return on Capital

-148.16%

Return on Assets

-16.31%

Earnings Yield

-100.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.95M

Shares Outstanding

6.08M

Volume

20.56K

Avg. Volume

215.59K

Financials (TTM)

Gross Profit

$6.16M

Operating Income

-$10.54M

EBITDA

-$7.91M

Operating Cash Flow

-$8.20M

Capital Expenditure

-$12.00K

Free Cash Flow

-$8.21M

Cash & ST Invst.

$3.97M

Total Debt

$1.07M

RedHill Biopharma Performance Analysis

RedHill Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 61,558,193	-28.3%
2023	2023-12-31	USD 6,513,173	-89.4%
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 288,269	N/A

RedHill Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2025-03-31	-25.4%
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A

RedHill Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1,152.77	-45.2%
2023	2023-12-31	USD 92.06	N/A
2024	2024-12-31	USD -6.73	N/A
2025	2025-12-31	USD -0.10	-98.5%

RedHill Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2025-03-31	N/A
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2025YOY CHG

Revenue

$2.04M

+58.6%

Gross Profit

$1.24M

+111.6%

Gross Margin

60.60%

N/A

Market Cap

$3.95M

N/A

Market Cap/Employee

$304.05K

N/A

Employees

N/A

Net Income

-$2.07M

-33.8%

EBITDA

-$2.11M

+47.6%

Quarterly Fundamentals

Name

Q2 2025YOY CHG

Total Cash

$3.97M

-14.0%

Total Debt

$1.07M

+200.6%

Accounts Receivable

$2.48M

-30.5%

Inventory

$0.00

-100.0%

Long Term Debt

$900.00K

+29900.0%

Short Term Debt

$170.00K

-75.9%

Return on Assets

-16.31%

N/A

Return on Invested Capital

-71.49%

N/A

Free Cash Flow

-$2.51M

+18.9%

Operating Cash Flow

-$2.51M

+18.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

FLGCFlora Growth Corp.

FLGCFlora Growth Corp.$7.79-32.14%

CNSPCNS Pharmaceuticals, Inc.

CNSPCNS Pharmaceuticals, Inc.$5.79-0.46%

BGMSBio Green Med Solution, Inc.

BGMSBio Green Med Solution, Inc.$0.88-1.12%

SXTP60 Degrees Pharmaceuticals, Inc.

SXTP60 Degrees Pharmaceuticals, Inc.$1.14-2.56%

IMCCIM Cannabis Corp.

IMCCIM Cannabis Corp.$0.13+8.55%

GCTKGlucoTrack, Inc.

GCTKGlucoTrack, Inc.$0.41-14.74%

AKANAkanda Corp.

AKANAkanda Corp.$5.39+1.51%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$41.55-0.05%

NVDANvidia

NVDANvidia$206.28+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.80+0.07%

INTCIntel

INTCIntel$90.92+0.01%

AMZNAmazon

AMZNAmazon$284.32+0.05%

SOFISoFi Technologies

SOFISoFi Technologies$17.97+0.10%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$113.65+0.05%

Questions About RDHL

What is the current price of RedHill Biopharma?

RedHill Biopharma is trading at $0.65 per share.

What is the 52-week range for RedHill Biopharma?

Over the past 52 weeks, RedHill Biopharma has traded between $0.63 and $2.79.

How much debt does RedHill Biopharma have?

As of the most recent reporting period, RedHill Biopharma reported total debt of $1.07M.

How much cash does RedHill Biopharma have on hand?

RedHill Biopharma reported $3.97M in cash and cash equivalents in its most recent financial results.

What is RedHill Biopharma’s dividend yield?

RedHill Biopharma does not currently have a dividend yield.

RedHill Biopharma(NASDAQ) RDHL

RedHill Biopharma Financials at a Glance

RDHL News

Why RedHill Biopharma Blasted 12% Higher Today

Why RedHill Biopharma Stock Is Getting Crushed Today

Why RedHill Biopharma Stock Jumped on Tuesday

Why RedHill Biopharma Stock Is Tanking Today

Why RedHill Biopharma Is Trouncing the Market Today

Here's Why RedHill Biopharma Jumped on Monday

3 Biotech Stocks That Could Double Your Money

Why Redhill Biopharma Ltd. Stock Is Soaring Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About RedHill Biopharma

RDHL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

RedHill Biopharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RDHL

What is the current price of RedHill Biopharma?

What is the 52-week range for RedHill Biopharma?

How much debt does RedHill Biopharma have?

How much cash does RedHill Biopharma have on hand?

What is RedHill Biopharma’s dividend yield?

Premium Investing Services